117 related articles for article (PubMed ID: 31704813)
21. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
22. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis.
Abou-El-Naga IF; El Kerdany ED; Mady RF; Shalaby TI; Zaytoun EM
Parasitol Int; 2017 Dec; 66(6):735-747. PubMed ID: 28838776
[TBL] [Abstract][Full Text] [Related]
23. Lopinavir-Ritonavir: a new protease inhibitor.
Mangum EM; Graham KK
Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
[TBL] [Abstract][Full Text] [Related]
24. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
[TBL] [Abstract][Full Text] [Related]
25. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
[TBL] [Abstract][Full Text] [Related]
26. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
27. Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.
Fagone P; Mangano K; Quattrocchi C; Cavalli E; Mammana S; Lombardo GA; Pennisi V; Zocca MB; He M; Al-Abed Y; Nicoletti F
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):306-15. PubMed ID: 25903922
[TBL] [Abstract][Full Text] [Related]
28. The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.
Israr M; Mitchell D; Alam S; Dinello D; Kishel JJ; Meyers C
HIV Med; 2011 Mar; 12(3):145-56. PubMed ID: 20722750
[TBL] [Abstract][Full Text] [Related]
29. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
30. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Capel E; Auclair M; Caron-Debarle M; Capeau J
Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
[TBL] [Abstract][Full Text] [Related]
31. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Noor MA; Flint OP; Maa JF; Parker RA
AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
[TBL] [Abstract][Full Text] [Related]
32. HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.
Kariya R; Taura M; Suzu S; Kai H; Katano H; Okada S
Cancer Lett; 2014 Jan; 342(1):52-9. PubMed ID: 24012878
[TBL] [Abstract][Full Text] [Related]
33. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].
Zamora L; Gatell JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():2-6. PubMed ID: 25542868
[TBL] [Abstract][Full Text] [Related]
35. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
[TBL] [Abstract][Full Text] [Related]
36. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
[TBL] [Abstract][Full Text] [Related]
37. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
Na YJ; Lee DH; Kim JL; Kim BR; Park SH; Jo MJ; Jeong S; Kim HJ; Lee SY; Jeong YA; Oh SC
Int J Biochem Cell Biol; 2017 Aug; 89():147-156. PubMed ID: 28624529
[TBL] [Abstract][Full Text] [Related]
38. Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo.
Paskas S; Mazzon E; Basile MS; Cavalli E; Al-Abed Y; He M; Rakocevic S; Nicoletti F; Mijatovic S; Maksimovic-Ivanic D
Invest New Drugs; 2019 Oct; 37(5):1014-1028. PubMed ID: 30706336
[TBL] [Abstract][Full Text] [Related]
39. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
[TBL] [Abstract][Full Text] [Related]
40. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
